Biography
Dr. Aaron Devanathan is an Assistant Professor in the Department of Pharmacy and Therapeutics. He received his PharmD from the University of Pittsburgh and completed PGY1 Pharmacy Practice Residency at UNC Hospitals. He earned a PhD in Pharmaceutical Sciences and completed the UNC-Duke Collaborative Clinical Pharmacology T32 Postdoctoral Training Program at the UNC Eshelman School of Pharmacy before accepting a faculty position at the University of Pittsburgh. Dr. Devanathan leads the Certara Academic Center of Excellence program at PittPharmacy.
The Devanathan laboratory focuses on the clinical pharmacology of antiretrovirals and their disposition into biological matrices with the goal of understanding how antiretroviral pharmacology affects inflammatory processes related to HIV-associated comorbidities and vice versa.
In the News
Aaron Devanathan selected to serve on Editorial Board of Clinical Pharmacology & Therapeutics
Dr. Aaron Devanathan has been selected to serve on the Editorial Board of Clinical Pharmacology & Therapeutics (CPT), the flagship journal of...
Aaron Devanathan moderates PK/PD session at IDWeek 2025
Dr. Aaron Devanathan, principal investigator of the Devanathan Lab, served as a session moderate at IDWeek 2025, held in Atlanta,...
Devanathan lab showcases research excellence at 26th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs
Dr. Aaron Devanathan and Noah Neverette, a graduate student in the Clinical Pharmaceutical Scientist Program, represented the lab at the...
Featured Publications
Contemporary antiretroviral pharmacology in the male genital tract: implications for HIV treatment and prevention
Antimicrob Agents Chemother. 2026 May 6;70(5):e0140125. DOI: 10.1128/aac.01401-25. PMID: 41870063. Epub 2026 Mar 23.
Cardiovascular-kidney-metabolic syndrome in people with HIV: An emerging frontier for clinical pharmacology
Clin Pharmacol Ther. 2025 Dec 10:10.1002/cpt.70164. DOI: 10.1002/cpt.70164. PMID: 41368766.
Antiretroviral therapy and anesthesia: Considerations for lenacapavir
Anesth Analg. 2026 Jan 1;142(1):e1-e2. DOI: 10.1213/ANE.0000000000007770. PMID: 40956758.
